In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the ...

CWA Asset Management Group LLC acquired a new position in Organon & Co. (NYSE:OGN – Free Report) in the third quarter, ...

Incaier, the healthcare arm of Haier Group, has participated in the expo for five consecutive years. This year, more than 50 ...

Havas Health named Anna Maria Marra as CEO of Europe on Tuesday morning, a role in which she will lead and oversee all ...

Pfizer hired Marra all the way back in 2002, at which time the new Havas Health exec had spent a few years working at Merck ...

Her career spans more than 26 years across four continents, during which she has held key leadership roles in marketing, ...

On October 30, 2024, Shanghai Henlius Biotech and Organon announced that the FDA has accepted the Biologic License Application (BLA) for HLX14, a proposed biosimilar to PROLIA/XGEVA (denosumab). In ...

Organon's OGN short percent of float has risen 28.4% since its last report. The company recently reported that it has 12.53 ...

International Assets Investment Management LLC increased its holdings in Organon & Co. (NYSE:OGN – Free Report) by 1,851.8% in the third quarter, HoldingsChannel.com reports. The institutional ...

On Tuesday, Organon & Co (OGN) stock saw a decline, ending the day at $16.46 which represents a decrease of $-0.46 or -2.72% from the prior close of $16.92. The stock opened at $16.74 and touched a ...

InProcess-LSP are a young organization, founded in 2014, they have since emerged as providers of groundbreaking process analytical technology for nanoparticle characterization. This article provides a ...

The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...